Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 62332-556

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 62332-556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60 Bottle Label (Sacubitrilvalsartan 24 26)

Sacubitril and Valsartan Tablets 24 mg/26 mg film-coated oral tablets in a 60-tablet package from Alembic Pharmaceuticals Inc. The label includes dosage details, storage instructions, manufacturer information, and regulatory barcodes and numbers.*

FDA Label Image

Figure 7 (Sacubitrilvalsartan 7 Figure)

A comparative hazard ratio line graph showing the relationship between sacubitril and valsartan versus enalapril in the PARADIGM-HF trial and versus valsartan in the PARAGON-HF trial. The x-axis represents left ventricular ejection fraction at screening (%) ranging from 15 to 75. The y-axis shows the hazard ratio from 0.5 to 1.6, with solid lines representing hazard ratios and dashed lines indicating 95% confidence intervals.*

FDA Label Image

60 Bottle Label (Sacubitrilvalsartan 97103)

Label for sacubitril and valsartan tablets 97 mg/103 mg by Alembic Pharmaceuticals Inc. The label states the dosage form as film-coated tablets, contains 60 tablets, and specifies storage instructions at 25°C with permitted excursions. Manufacturer information and barcode are present.*

FDA Label Image

Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)

A plot showing geometric mean ratios and 90% confidence intervals for sacubitril (LBQ657) and valsartan comparing various population subgroups including renal impairment (mild to severe), hepatic impairment (mild/moderate), age groups (≥65 years vs 18 to 45 years), sex (male/female), and race (Asian, Caucasian, Black) relative to a reference group. The variables plotted are AUC and Cmax values with change relative to reference on the x-axes.*

FDA Label Image

Figure 1 (Sacubitrilvalsartan Fig1)

A chart titled 'Coadministered Drugs' comparing geometric mean ratios and 90% confidence intervals for various drugs relative to a reference. The x-axis shows change relative to reference from 0.5 to 2. Data include drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. Two symbols represent AUC (filled circle) and Cmax (open circle).*

FDA Label Image

Figure 3 (Sacubitrilvalsartan Fig3)

This image contains three Kaplan-Meier curve charts labeled Figure A, B, and C comparing sacubitril and valsartan with enalapril. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalizations, Figure B shows time to occurrence of cardiovascular death, and Figure C shows time to first occurrence of heart failure hospitalizations. Each chart plots cumulative failure rate percentage over time since randomization (days), including number at risk at various time points.*

FDA Label Image

Figure 4 (Sacubitrilvalsartan Fig4)

A forest plot chart comparing the effectiveness of sacubitril and valsartan to enalapril across various subgroups including age, gender, weight, race, region, NYHA class, kidney function, diabetes status, blood pressure, ejection fraction, and other clinical factors. The plot shows hazard ratios with 95% confidence intervals indicating treatment effects across these subpopulations.*

FDA Label Image

Figure 6 (Sacubitrilvalsartan Figur6)

A forest plot comparing the efficacy of sacubitril and valsartan versus valsartan alone across various subgroups. The plot displays rate ratios with 95% confidence intervals for factors such as age, gender, race, geographic region, baseline diabetic status, left ventricular ejection fraction, and other clinical parameters. Each subgroup is represented with a point estimate and confidence interval showing relative performance of the treatments.*

FDA Label Image

Figure 5 (Sacubitrilvalsartan Figure5)

A line graph depicting total heart failure hospitalizations and cardiovascular death over time in days since randomization, comparing sacubitril and valsartan versus valsartan alone in the PARAGON-HF study. The y-axis shows mean number of events per 100 patients, with sacubitril and valsartan showing fewer events over time.*

FDA Label Image

60 Tablets Bottle Label (Sacubitrilvalsartan mg 49 51)

Label for Sacubitril and Valsartan Tablets, 49 mg/51 mg film-coated tablets. The label indicates a package containing 60 tablets, manufactured by Alembic Pharmaceuticals Inc. It includes storage instructions, usage directions as prescription only, and manufacturing details for Alembic Pharmaceuticals Limited in Gujarat, India, and Alembic Pharmaceuticals, Inc. in Bedminster, USA.*

FDA Label Image

Structure (Sacubitrilvalsartan Str)

Chemical structure of sacubitril and valsartan, showing the molecular arrangement including sodium ions and water of hydration as part of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.